| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 65219-0131-20 | 65219-0131 | Cyclophosphamide | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Nov 17, 2023 | In Use | |
| 42254-0110-30 | 42254-0110 | METHOTREXATE | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec 7, 1953 | In Use | |
| 69945-0452-15 | 69945-0452 | sodium iodide i 131 | SODIUM IODIDE I 131 | 1.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Oct 27, 2015 | Jul 1, 2018 | No Longer Used |
| 00075-8005-01 | 00075-8005 | Docetaxel | Taxotere | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 4, 2012 | Dec 23, 2013 | No Longer Used | |
| 68180-0391-06 | 68180-0391 | IMATINIB | IMATINIB MESYLATE | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jul 8, 2019 | In Use | |
| 51285-0369-01 | 51285-0369 | Methotrexate | Trexall | 15.0 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | May 3, 2001 | In Use | |
| 50419-0171-03 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sep 27, 2012 | In Use | |
| 16729-0108-11 | 16729-0108 | Mitomycin | Mitomycin | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Jun 10, 2009 | In Use | |
| 47335-0930-74 | 47335-0930 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
| 57277-0106-15 | 57277-0106 | carboplatin Injection | Carboplatin | 150.0 mg/5mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sep 29, 2016 | In Use | |
| 68001-0265-22 | 68001-0265 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Nov 14, 2013 | In Use | |
| 63739-0932-11 | 63739-0932 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan 1, 2015 | Mar 31, 2017 | In Use |
| 69539-0091-30 | 69539-0091 | Erlotinib Hydrochloride | Erlotinib Hydrochloride | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 11, 2021 | In Use | |
| 68382-0244-16 | 68382-0244 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 72603-0420-01 | 72603-0420 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 11, 2024 | Mar 31, 2027 | In Use |
| 00781-3528-10 | 00781-3528 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Apr 8, 2024 | In Use | |
| 00143-9547-01 | 00143-9547 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 1, 1996 | In Use | |
| 55150-0513-01 | 55150-0513 | METHOTREXATE | METHOTREXATE | 250.0 mg/10mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intramuscular, Intrathecal, Intravenous, Subcutaneous | Sep 11, 2024 | In Use | |
| 40051-0609-12 | 40051-0609 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
| 73116-0215-28 | 73116-0215 | Duvelisib | COPIKTRA | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 62484-0020-01 | 62484-0020 | Purixan | Purixan | 20.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Oral | Apr 28, 2014 | In Use | |
| 70771-1395-05 | 70771-1395 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 67184-0533-01 | 67184-0533 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 21, 2022 | In Use | |
| 50419-0171-00 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sep 27, 2012 | In Use | |
| 60505-3803-07 | 60505-3803 | Nilotinib | Nilotinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 23, 2025 | In Use |
Found 12159 results — Export these results
Home